Charles River Laboratories International EV/EBIT CRL

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2011.

Today, Oct 23, 2026: 26.0×
10-year median: 22.3×
Against its 10-year history: 76th; percentile: 0 is its lowest day, 100 its highest
10-year range: 13.2× to 49.0×
Peer median: 30.9×

Charles River Laboratories International's EV/EBIT is 26.0× as of Oct 23, 2026.

That is above its ten-year median of 22.3×, higher than on 76% of days in the last ten years.

Over that time it ranged from 13.2× in May 2026 to 49.0× in Sep 2021.

The median for 10 diagnostics and research stocks of a similar size is 30.9×.

EV/EBIT over time

median 22.3×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	26.0×	13.2×	28.0×
2025	26.1×	13.7×	26.1×
2024	19.8×	19.1×	24.6×
2023	21.1×	16.3×	23.4×
2022	20.9×	18.5×	37.7×
2021	39.7×	35.5×	49.0×
2020	34.4×	19.4×	37.3×
2019	26.6×	22.1×	26.6×
2018	22.4×	19.0×	27.2×
2017	21.0×	19.7×	23.6×
2016	21.3×	19.6×	23.9×
2015	23.1×	19.5×	25.5×
2014	22.1×	18.6×	22.7×
2013	18.6×	13.8×	18.6×
2012	13.2×	12.1×	14.9×
2011	12.2×	12.0×	26.1×

Against its peers

Companies in Medical - Diagnostics & Research nearest Charles River Laboratories International's size, closest first, today.

Company	EV/EBIT
CRLCharles River Laboratories International	26.0×
RVTYRevvity	46.0×
MEDPMedpace	31.4×
LHLabcorp	21.6×
DGXQuest Diagnostics	19.5×
BIOBio-Rad Laboratories	40.2×
CAICaris Life Sciences	56.4×
MTDMettler-Toledo International	30.5×
ILMNIllumina	47.7×
LNTHLantheus	20.6×
IDXXIDEXX Laboratories	30.3×
Peer median	30.9×

Where Charles River Laboratories International ranks

#7of 25Diagnostics and research stocks with the lowest EV/EBIT

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Charles River Laboratories International

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.